Metrodora Therapeutics

Metrodora Therapeutics is a biotechnology company dedicated to developing first-in-class therapies for disorders of the neuroimmune axis. The company focuses on complex, multisystem conditions such as Postural Orthostatic Tachycardia Syndrome (POTS), gastroparesis, and Ehlers-Danlos Syndrome, which currently lack effective treatment options. By integrating deep clinical insights from the Metrodora Institute with advanced molecular profiling, the company identifies novel therapeutic targets at the intersection of the nervous and immune systems. Metrodora utilizes a precision medicine approach to develop a pipeline of small molecules, biologics, and gene therapies. Their mission is to restore systemic balance and improve the lives of patients suffering from chronic, debilitating neuroimmune conditions. The company is backed by leading life science investors and led by experts in neurology, immunology, and drug development.